Universal Diagnostics

UniversalDx is a health-tech startup that operates in the medical diagnostics market, specifically focusing on cancer detection. The company has developed a liquid biopsy test, Signal-C®, which can accurately detect Colorectal Cancer and Advanced Adenomas. This test uses a combination of multi-omics, computational biology, and machine learning to identify cancer signals, boasting a sensitivity of 92% and a specificity of 94%. In simpler terms, this means the test is highly accurate in both identifying those who have the disease (sensitivity) and correctly ruling out those who do not (specificity).

The company's primary clients are healthcare providers and patients who require cancer screening. UniversalDx's business model revolves around providing this innovative diagnostic tool to the healthcare sector. They generate revenue by selling the Signal-C® test to healthcare providers or directly to patients.

A significant part of their strategy is their collaboration with Quest Diagnostics, a leading provider of diagnostic information services. This partnership will help UniversalDx to accelerate the impact of their cancer detection test and increase its availability. Once the Signal-C® test receives FDA approval, it will be accessible through the Quest Diagnostics network, allowing a larger share of the U.S. population to be screened for colorectal cancer. This could potentially reduce both the incidence and mortality rates of this disease.

Keywords: Health-tech, Cancer Detection, Liquid Biopsy, Colorectal Cancer, Advanced Adenomas, Multi-omics, Computational Biology, Machine Learning, Diagnostic Tool, Quest Diagnostics.